2018年2月15日 · We found that the activated EGFR signaling could bypass RhoA to promote the expression of YAP (Yes-associated protein), the core effector of the Hippo signaling, and its downstream target Cyr61.

Our results suggest that YAP expression is associated with a poor prognosis for cervical cancer. TGF-α and amphiregulin (AREG), via EGFR, inhibit the Hippo signaling pathway and activate YAP to induce cervical cancer cell proliferation and migration.

2021年11月1日 · Our findings suggest that EGFR-YAP/TAZ signaling plays a growth-promoting role in cancers harboring EGFR alterations, and that inhibition of YAP/TAZ in combination with EGFR might be...

2020年9月2日 · Through an integrated transcriptomic, proteomic, and drug screening approach, we identified activation of the yes-associated protein (YAP) and forkhead box protein M1 (FOXM1) axis as a driver of EMT-associated EGFR TKI resistance.

2022年7月8日 · Our work highlights that EGFR-PI3K-PDK1-dependent YAP activation plays a crucial role in the formation of PVR. Targeting EGFR and the YAP pathway provides promising therapeutic treatments for PVR.

2023年8月17日 · Comprehensive transcriptional analysis revealed that AXL activates YAP through a novel mechanism: AXL heterodimerizes with EGFR, thereby activating YAP via the EGFR–LATS1/2 axis. The...

2017年12月1日 · In EGFR-addicted lung cancer cell lines (HCC4006 and HCC827) rendered resistant to several EGFR inhibitors, we observed that resistance was associated to YAP activation. Indeed, YAP silencing impaired the maintenance of resistance, while YAP overexpression decreased the responsiveness to EGFR inhibitors in sensitive parental cells.

2015年6月1日 · YAP1 up-regulation of EGFR plays an important role in conferring therapy resistance in EC cells. Verteporfin, a small molecular inhibitor of YAP1, effectively diminishes both YAP and EGFR expression and sensitizes cells to cytotoxics. Therefore, targeting YAP-EGFR axis may be more promising than targeting EGFR alone in EC.

2017年11月11日 · The reported data demonstrate that YAP and its downstream target AXL play a crucial role in resistance to EGFR TKIs and suggest that a combined inhibition of EGFR and the YAP/AXL axis could be a good therapeutic option in selected NSCLC patients.

2020年1月13日 · In this issue of Cancer Cell, Kurppa et al. demonstrated that a senescence-like state enables lung cancer cells to survive dual inhibition of EGFR and MEK. This was mediated by the YAP/TEAD pathway, which drives epigenomic reprogramming and EMT to counteract apoptosis. Therapeutic resistance is a primary concern in cancer treatment.